Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS002 in primary hypercholesterolemia and mixed dyslipidemia
CTR20201907Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ongericimab in hypercholesterolemia, familial hypercholesterolemia (FH), combined dyslipidaemia, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Sep 2020; status: completed.
02
Drugs
ongericimab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)combined dyslipidaemia
Beyond the preview
Go deeper on CTR20201907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201907.